ZytokinTherapy for childhood uveitis. Biologics: Too often - too late?;Uveitistherapie im Kindesalter. Biologika: Zu oft - zu spät?

Ophthalmologe

Volumn 108, Issue 3, 2011, Pages 213-221

  Mackensen, F ^a   Lutz, T ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biologics; Childhood uveitis; Cytokine; Juvenile idiopathic arthritis; Tumor necrosis factor

Indexed keywords

ADALIMUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; GOLIMUMAB; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MACROGOL DERIVATIVE; METHOTREXATE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; BLINDNESS; CHEMICALLY INDUCED DISORDER; CHILD; DOSE RESPONSE; DRUG ANTAGONISM; DRUG COMBINATION; HUMAN; IMMUNOLOGY; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOMA; NEOPLASM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; UVEITIS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL PRODUCTS; BLINDNESS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA; METHOTREXATE; NEOPLASMS; POLYETHYLENE GLYCOLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 79952986269     PISSN: 0941293X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00347-010-2260-2     Document Type: Review

References (46)

1. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften et al (2008) Leitlinien der Gesellschaft für Kinderheilkunde und Jugendrheumatologie. www. uni-duesseldorf. de/AWMF/II/027-020. htm.
2. Ardoin SP, Kredich D, Rabinovich E et al (2007) Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am J Ophthalmol 144: 844-849.
3. Biester S, Deuter C, Michels H et al (2007) Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 91: 319-324.
4. Calogiuri G, Ventura MT, Mason L et al (2008) Hypersensitivity reactions to last generation chimeric, humanized [correction of umanized] and human recombinant monoclonal antibodies for therapeutic use. Curr Pharm Des 14: 2883-2891.
5. Charles C, Gafni A, Whelan T (1997) Shared decision-making in the medical encounter: What does it mean? (or it takes at least two to tango). Soc Sci Med 44: 681-692.
6. Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344: 907-916.
7. Davis Jl, Dacanay LM, Holland GN et al (2003) Laser flare photometry and complications of chronic uveitis in children. Am J Ophthalmol 135: 763-771.
8. Diak P, Siegel J, La Grenade L et al (2010) Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 62: 2517-2524.
9. Fantazzini P, Garavaglia C, Gomez S et al (2007) Chondrocyte-alginate bioconstructs: a nuclear magnetic resonance relaxation study. J Biomed Mater Res A 83: 345-353.
10. Foeldvari I, Nielsen S, Kummerle-Deschner J et al (2007) Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J Rheumatol 34: 1146-1150.
11. Gallagher M, Quinones K, Cervantes-Castaneda RA et al (2007) Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 91: 1341-1344.
12. Goebel JC, Roesel M, Heinz C et al (2011) Azathioprine as a treatment option for uveitis in patients with juvenile idiopathic arthritis. Br J Ophthalmol 95: 209-213.
13. Heiligenhaus A, Horneff G, Greiner K et al (2007) Inhibitors of tumour necrosis factor-alpha for the treatment of arthritis and uveitis in childhood. Klin Monatsbl Augenheilkd 224: 526-531.
14. Heiligenhaus A, Mingels A, Heinz C et al (2007) Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol 17: 743-748.
15. Heiligenhaus A, Niewerth M, Ganser G et al (2007) Prevalence and complications of uveitis in juvenile idiopathic arthritis in a population-based nation-wide study in Germany: suggested modification of the current screening guidelines. Rheumatology (Oxford) 46: 1015-1019.
16. Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140: 509-516.
17. Kahn P, Weiss M, Imundo LF et al (2006) Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 113: 860-864.
18. Kayton Ml (2007) Cancer and pediatric inflammatory bowel disease. Semin Pediatr Surg 16: 205-213.
19. Kenawy N, Cleary G, Mewar D et al (2010) Abatacept: a potential therapy in refractory cases of juvenile idiopathic arthritis-associated uveitis. Graefes Arch Clin Exp Ophthalmol (Oct 5 Epub).
20. Kilmartin DJ, Forrester JV, Dick AD (1998) Cyclosporine-induced resolution of choroidal neovascularization associated with sympathetic ophthalmia. Arch Ophthalmol 116: 249-250.
21. Lim LL, Fraunfelder FW, Rosenbaum JT (2007) Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 56: 3248-3252.
22. Minden K (2009) Adult outcomes of patients with juvenile idiopathic arthritis. Horm Res 72(Suppl 1): 20-25.
23. Rajaraman RT, Kimura Y, LI S et al (2006) Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology 113: 308-314.
24. Reiff A, Takei S, Sadeghi S et al (2001) Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 44: 1411-1415.
25. Rosenberg KD, Feuer WJ, Davis Jl (2004) Ocular complications of pediatric uveitis. Ophthalmology 111: 2299-2306.
26. Rosh JR, Gross T, Mamula P et al (2007) Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 13: 1024-1030.
27. Saurenmann RK, Levin AV, Rose JB et al (2006) Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology 45: 982-989.
28. Sharma SM, Ramanan AV, Riley P et al (2007) Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Ann Rheum Dis 66: 840-841.
29. Simonini G, Taddio A, Cattalini M et al (2010) Prevention of flare recurrences in childhood refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res (Hoboken) (Nov 15 Epub).
30. Simonini G, Zannin ME, Caputo R et al (2008) Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology 47: 1510-1514.
31. Smith JA, Mackensen F, Sen HN et al (2009) Epidemiology and course of disease in childhood uveitis. Ophthalmology 116: 1544-1551.
32. Smith JA, Thompson DJ, Whitcup SM et al (2005) A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 53: 18-23.
33. Smith JR, Levinson RD, Holland GN et al (2001) Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 45: 252-257.
34. Southwood TR, Foster He, Davidson JE et al (2011) Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. Rheumatology 50: 184-195.
35. Svenson M, Geborek P, Saxne T et al (2007) Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology 46: 1828-1834.
36. Tappeiner C, Roesel M, Heinz C et al (2009) Limited value of cyclosporine A for the treatment of patients with uveitis associated with juvenile idiopathic arthritis. Eye (Lond) 23: 1192-1198.
37. Tran TH, De Smet MD, Bodaghi B et al (2008) Uveitic macular oedema: correlation between optical coherence tomography patterns with visual acuity and fluorescein angiography. Br J Ophthalmol 92: 922-927.
38. Tugal-Tutkun I, Ayranci O, Kasapcopur O et al (2008) Retrospective analysis of children with uveitis treated with infliximab. J AAPOS 12: 611-613.
39. Tugal-Tutkun I, Havrlikova K, Power WJ et al (1996) Changing patterns in uveitis of childhood. Ophthalmology 103: 375-383.
40. Tugal-Tutkun I, Herbort CP (2010) Laser flare photometry: a noninvasive, objective, and quantitative method to measure intraocular inflammation. Int Ophthalmol 30: 453-464.
41. Tynjala P, Kotaniemi K, Lindahl P et al (2008) Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology 47: 339-344.
42. Tynjala P, Lindahl P, Honkanen V et al (2007) Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 66: 548-550.
43. Vazquez-Cobian LB, Flynn T, Lehman TJ (2006) Adalimumab therapy for childhood uveitis. J Peds 149: 572-575.
44. Winterhalter S, Niehues T (2008) TNFalpha-blocking agents or conventional immunosuppressive drugs in the therapy of children with uveitis? - An evidence based approach. Klin Padiatr 220: 342-347.
45. Zulian F, Balzarin M, Falcini F et al (2010) Abatacept for severe anti-tumor necrosis factor alpha refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care Res (Hoboken) 62: 821-825.
46. Pleyer U, Mackensen F, Winterhalter S et al (2011) Anti-TNF-Therapie bei Uveitis. Eine Standortbestimmung. Ophthalmologe 108: 13-20.